EORTC
European Organisation for Research and Treatment of Cancer

Cancer Medicines Forum

Rationale and Achievements

Denis Lacombe 5th April 2024

We would not be here today without….

- EMA Management: Emer Cooke
  - Francesco Pignatti: Scientific Advisor for Oncology
  - Caroline Voltz: Scientific Lead, Haematology and Oncology Division
- Minister Vandenbroucke: Vice Premier and Minister for Social Affairs and Public Health and his Cabinet: Anouk Waeytens, Anna Kubina, Gloria Ghequiere
- Representatives of the societies and organisations, members of the CMF
- The unconditional support of the EORTC Board of Directors represented by its president Prof W. van der Graaf
- Research Fellows: Robbe Saesen and Fabio Borges

EORTC
European Organisation for Research and Treatment of Cancer

EORTC
European Organisation for Research and Treatment of Cancer

Why did the CMF get started?

Once upon a time in the late years 2000s….

When we needed to re-think why and how!



Optimisation Applied Multidisciplinary Clinical Research

E.g.: Combination
Sequence / Dosage
De-escalation
Duration
Benchmarking
Specific populations

Health System Optimisation

Health Services & Implementation Research

Access / costs
Guidelines
Cancer control plans

Clinically relevant endpoints for patients

EORTC
European Organisation for Research and Treatment of Cancer

Why EORTC stimulated the CMF?



EORTC
European Organisation for Research and Treatment of Cancer

It has been a journey… today is an important milestone



…….2013

2013-2019

2019-2024



Burock S, Meunier F, Lacombe D. **How can innovative forms of clinical research contribute to deliver affordable cancer care in an evolving health care environment?** Eur J Cancer 2013; 49:2777-2783.

EORTC
European Organisation for Research and Treatment of Cancer

Key questions to the policy makers

- How to address the gap between supra-national versus national competences?
- If treatment optimisation is to be structured in the process: when, how and who?
- How do we re-engineer the sequence of questions from development into access?
- How do we prioritise questions and select the most appropriate methodology?
- Can Pragmatic clinical trials help structuring and addressing some of the issues?
- How do we structure independent multidisciplinary clinical research in the EU?

Need for strategic intelligence approaches

EORTC
European Organisation for Research and Treatment of Cancer

The Future of Cancer Treatment is Combinatorial

Multidimensional data

Authorisation



Optimal access

EORTC
European Organisation for Research and Treatment of Cancer

A new continuum to be set up ….Re-engineer….



EORTC
European Organisation for Research and Treatment of Cancer

Objectives of the Cancer Medicines Forum

To serve as a direct and official communication channel with the academic community in oncology

To identify key research questions and best methodological approach to improve the clinical use of cancer medicines

To discuss the uptake of academic work in the wider context of regulatory decision-making in oncology

Treatment optimisation

Focus on academia with other stakeholders



Structuring Treatment Optimisation

EORTC
European Organisation for Research and Treatment of Cancer

The clinical question is the starting point
The design is just to mean to answer a question



Thick lines represent the default route to deliver evidence for trial design selection

EORTC
European Organisation for Research and Treatment of Cancer

Addressing What-When-How-Who



EORTC
European Organisation for Research and Treatment of Cancer

Treatment Optimisation is a spectrum

	What	Who	How	feasibility
Early stage Pre-licensing	Dose/safety R/B	Manufacturer	Regulatory process (i.e Optimus)	Explanatory trials
Late stage Post licensing	Combo, de-escalation, population, duration, schedule	Manufacturer academia	Public trial eco-system (adjust legislation)	Pragmatic trials Registry based trials Platform trials

Operational challenges to implementation

Methodological research:
Pragmatic trials, TwiCs…
Recruitment and ethics

Adapt the clinical research environment
Education of stakeholders

Reporting and access to datasets

Health economic dimension and funding

Continued refinement of the pyramid of evidence-based medicine

Thorough and timely information to guide patient treatment

Continued understanding of patient populations as science evolves
(LOH 1p/19q gliomas, TIL Breast cancer..)



EORTC
European Organisation for Research and Treatment of Cancer